LENZ Therapeutics, Inc. (NASDAQ:LENZ) Short Interest Up 11.9% in December

LENZ Therapeutics, Inc. (NASDAQ:LENZ) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,530,000 shares, a growth of 11.9% from the December 15th total of 2,260,000 shares. Based on an average trading volume of 154,500 shares, the days-to-cover ratio is presently 16.4 days. Approximately 11.3% of the shares of the stock are sold short.

LENZ Therapeutics Stock Up 0.4 %

NASDAQ LENZ traded up $0.10 on Friday, reaching $22.50. 143,402 shares of the company’s stock traded hands, compared to its average volume of 153,115. LENZ Therapeutics has a 12 month low of $14.42 and a 12 month high of $38.93. The stock has a 50-day simple moving average of $31.50 and a 200 day simple moving average of $26.34.

LENZ Therapeutics (NASDAQ:LENZ) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter in the prior year, the business posted ($1.33) EPS. As a group, analysts expect that LENZ Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LENZ. SG Americas Securities LLC bought a new position in shares of LENZ Therapeutics in the third quarter worth approximately $107,000. Squarepoint Ops LLC bought a new stake in LENZ Therapeutics in the 2nd quarter worth $181,000. MetLife Investment Management LLC bought a new stake in LENZ Therapeutics in the 3rd quarter worth $182,000. GSA Capital Partners LLP purchased a new position in shares of LENZ Therapeutics in the third quarter valued at about $246,000. Finally, Jane Street Group LLC bought a new position in shares of LENZ Therapeutics during the third quarter valued at about $286,000. Hedge funds and other institutional investors own 54.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on LENZ shares. Raymond James began coverage on shares of LENZ Therapeutics in a research report on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, LENZ Therapeutics currently has an average rating of “Buy” and a consensus target price of $35.40.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.